high Gr-1 high myeloid cells and dendritic cells (DCs) under basal conditions, as well as on a variety of leucocyte subsets following inflammatory stimuli or in vitro cell culture. However, previous studies assessing CLEC-2 expression failed to use CLEC-2-deficient mice as negative controls and instead relied heavily on single antibody clones. Here, we generated CLEC-2-deficient adult mice using two independent approaches and employed two anti-mouse CLEC-2 antibody clones to investigate surface expression on hematopoietic cells from peripheral blood and secondary lymphoid organs. We rule out constitutive CLEC-2 expression on resting DCs and show that CLEC-2 is upregulated in response to LPS-induced systemic inflammation in a small subset of activated DCs isolated from the mesenteric lymph nodes but not the spleen. Moreover, we demonstrate for the first time that peripheral blood B lymphocytes present exogenously derived CLEC-2 and suggest that both circulating B lymphocytes and CD11b high Gr-1 high myeloid cells lose
Introduction
Many physiological functions are critically regulated by finetuned interactions between diverse subsets of hematopoietic and nonhematopoietic cells within primary and secondary lymphoid organs (SLOs) as well as in the circulation. These interactions are mediated by surface receptors or secreted molecules that display complex cellular, spatial, and temporal expression patterns. A deep understanding of these patterns is required for a full knowledge of their physiological significance and for effective therapeutic intervention. For example, expression of receptor activator of NFκB ligand by bone osteoblasts regulates bone density while its expression by developing thymocytes regulates medullary thymic epithelial cell maturation (for review; [1] ).
A similar scenario can be considered for the C-type lectin-like receptor 2 (CLEC-2) and its ligand podoplanin (PDPN), which are involved in a variety of physiological and pathophysiological processes (for review: [2] ). While CLEC-2 expression is restricted to hematopoietic cells, PDPN is more ubiquitously expressed, with constitutive expression in the lungs [3] , kidneys [4] , brain [3] , thymus [5] , SLOs [6, 7] , lymphatic vessels, and bones [8] . PDPN expression is also upregulated at the leading edge of tumors and in additional hematopoietic and nonhematopoietic cell types during inflammation (for review: [2] ). CLEC-2/PDPN interactions play essential roles in the immune system, as they prevent blood-lymph mixing [9] [10] [11] , are required for lymph node (LN) development [12] and maintenance of LN vascular integrity [12, 13] and contribute to the generation of optimal adaptive immune responses [12, 14, 15] .
CLEC-2 surface expression on platelets was first demonstrated in humans [16] and soon after in mouse [17] and chicken [18] . The expression of CLEC-2 and its RNA transcript -encoded by the C-type lectin domain family 1, member B (Clec1b) genehas also been studied in leucocytes isolated from different species leading to a rather confusing mosaic of results. While CLEC-2 is absent from chicken leucocytes [18] and restricted to liverresident Küppfer cells in human [19] [20] [21] [22] , a much broader expression profile of CLEC-2/Clec1b has been reported in rodent leucocytes, particularly in mice.
While one report claims that mouse CLEC-2 surface expression by leucocytes is restricted to monocytes and liver-resident Küppfer cells [20] , other studies using a different antibody clone (17D9), or the fusion protein PDPN-Fc, reported that CLEC-2 is constitutively expressed by CD11b high Gr-1 high cells isolated from bone marrow (BM) and whole blood, splenic B lymphocytes, a small subset of splenic natural killer (NK) cells, splenic plasmacytoid dendritic cells (pDCs), splenic conventional DCs (cDCs), GM-CSF stimulated BM-derived DCs (BMDCs), Flt3L BMDCs, as well as peripheral LN DCs [19, 23, 24] . With the exception of NKT cells and T lymphocytes, in vivo LPS challenge has been reported to upregulate CLEC-2 expression in almost all splenic leucocyte subsets as well as peripheral LN DCs [23, 24] . In a thioglycolate-induced peritoneal inflammation model, CLEC-2 expression was observed in F4/80 + macrophages but not in CD11b high Gr-1 high cells [19, 23] .
Notably, CLEC-2-deficient negative control cells were not included in most of these studies [19, 23] . Our study aimed to clarify these contradictory findings and improve our understanding of CLEC-2 expression on mouse leucocytes. These results have important physiological consequences that will be discussed below. Fig. 1 ).
Results and discussion
In parallel, we investigated CLEC-2 expression on hematopoietic cells isolated from lethally irradiated wild-type (WT) adult mice reconstituted with foetal liver (FL) cells from E14.5 Clec1b
−/− embryos [25] . This second experimental strategy was used to rule out potential side effects of tamoxifen on CLEC-2 expression. It is known that sex steroid hormones and their synthetic derivatives (such as tamoxifen) affect hematopoiesis due to the presence of estrogen receptors on most immune cells [26, 27] . Moreover, tamoxifen has anti-inflammatory effects that could counteract LPS-mediated proinflammatory challenges [28] [29] [30] . In addition, we used two different antibody clones, 17D9 [19, 23] and INU1 [31] (Fig. 1A) , confirming the efficiency of our inducible genetic mouse model. On platelets, INU1 staining was found to be weaker than 17D9 staining in both control animals (Clec1b fl/fl mice treated with tamoxifen and Clec1b fl/fl xRosa26 +/creERT2 mice fed with normal diet). Furthermore, the geometric mean fluorescence intensity associated with 17D9 binding to leucocytes was on average threefold lower than that observed on platelets (Fig. 1A) , while INU1 discrimination power was too weak for detecting CLEC-2 on leucocytes (Fig. 1A) . As a result, we solely used the 17D9 clone to further investigate CLEC-2 expression on leucocytes.
In both the tamoxifen-inducible and radiation chimeric CLEC-2-deficient mouse models, the levels of 17D9 binding to circulating B lymphocytes were significantly reduced compared to controls ( Fig. 1A and B) , suggesting that peripheral blood B lymphocytes constitutively express CLEC-2. Although CLEC-2 appeared to be downregulated on circulating B lymphocytes following LPS treatment in chimeric mice, this was not statistically significant (Fig.  1B) Fig. 1 ). Similarly, after LPS challenge, 17D9 acquired the ability to bind to Clec1b −/− CD11b high Gr-1 high cells leading to a 3.7-fold higher geometric mean fluorescence intensity than in equivalent unstimulated cells (Fig. 1B ). This suggests that 17D9 binds to CD11b high Gr-1 high cells in a CLEC-2-independent manner following LPS activation. In T lymphocytes, there was no evidence for 17D9 binding in any of our experimental conditions (Supporting Information Fig. 3 ). From these findings, we suggest that mouse peripheral blood B lymphocytes and CD11b high Gr-1 high cells present CLEC-2 on their surface at a much lower level than platelets. These data contrast with the lack of evidence for CLEC-2 expression in peripheral blood leucocytes in chickens or humans [18, 21] and with the absence of significant Clec1b transcripts in human leucocyte subsets according to microarray analyses on the BioGPS database [21, 36] . This indicates that, while CLEC-2 expression by platelets is conserved through species, the presence of CLEC-2 on B lymphocytes and CD11b high Gr-1 high cells is specific to mice. Whether the presence of CLEC-2 on these cells provides any particular features to the mouse immunological system remains unknown. Our data add to previous reports establishing important differences between the mouse and human immune systems [37] . high . After mRNA isolation and cDNA preamplification for the genes of interest, the samples were analyzed by quantitative PCR. The signal for Clec1b was normalized against the house-keeping gene Actnb (β-actin). Total BM isolated from PBS-injected mice was used as positive control while the T cells coming from these animals were used as reference to set the arbitrary unit. Each population was isolated from three to five independent cell sorting experiments including one LPS-injected and one PBS-injected mouse for each cell sorting, with the exception of the F4/80 pos CD11b int control and LPS-stimulated cells for which n = 2 experiments. Data are shown as mean + SEM. Statistical significance was measured by a Mann-Whitney test with a 95% confidence interval where: *p < 0.05; **p < 0.005; ***p < 0.0005; N.S., not significant. Figs. 4 and 5) . These results, that demonstrate a lack of CLEC-2 expression on these leucocytes, contradict previous observations made using the 17D9 antibody clone and PDPN-Fc recombinant protein that suggested that mouse CLEC-2 was constitutively expressed on all these cell types in spleen and on peripheral LNs' cDCs [23, 24] . Moreover, we could not detect significant Clec1b transcript levels in most of the leucocyte populations isolated from the spleen and the MLN (Fig. 2E) . The absence of Clec1b transcripts in most resting leucocytes is supported by two independent microarray analyses performed by the ImmGen [38] and BioGPS [36] consortia (Supporting Information Fig. 6 ). Interestingly, in agreement with the ImmGen database, we did observe that CD11b int F4/80 pos red pulp splenic macrophages express high levels of Clec1b transcripts (Fig. 2E) . However, we were unable to detect surface CLEC-2 on the surface of these cells when comparing our FL-reconstituted animals (data not shown).
Given that F4/80 pos red pulp splenic macrophages, which express PDPN, play a key physiological role in the clearance of senescent blood erythrocytes and platelets by phagocytosis [6, 39, 40] , the Clec1b transcripts detected in these cells are likely to derive from engulfed platelets. These results suggest that CLEC-2 surface expression by peripheral blood B lymphocytes and CD11b high Gr-1 high cells (Fig. 1) is lost upon entry into SLOs (Fig. 2) . The majority of mouse B lymphocytes and pre-cDC monocytes migrating from peripheral blood toward LNs enter via high endothelial venules (HEVs), arriving in the T-cell zone, which is rich in PDPN pos fibroblastic reticular cells (FRCs) [41] . (Fig. 2) , supporting the observation that circulating activated B lymphocytes downregulate CLEC-2 before entering into SLOs (Fig. 1B) . Kerrigan and collaborators have suggested the same CLEC-2 downregulation process by circulating CD11b high Gr-1 high cells upon reaching inflammatory sites [19] . As entry to both SLOs and inflammatory sites requires leucocyte rolling, arrest, and transendothelial migration [41] , it is tempting to suggest that CLEC-2 downregulation or shedding by these leucocytes facilitates the completion of this three-step mechanism. Indeed, it has been shown that the shedding of transmembrane molecules is essential for leucocyte transendothelial migration [43] [44] [45] [46] . We hypothesize that CLEC-2 could be lost via the same mechanisms. CD11b high Gr-1 high cells, pDCs, and CD11b neg/int cDCs isolated from LPS-stimulated Clec1b −/− mice exhibited a higher level of 17D9 binding than Clec1b −/− nonchallenged counterparts. Once again, these results indicate that the 17D9 antibody clone has the capacity to bind LPS-stimulated leucocytes in a CLEC-2-independent manner. The lack of Clec1b transcript upregulation in LPS-stimulated leucocytes (Fig. 2E ) provides further evidence to support this conclusion and challenges previously described LPSinduced CLEC-2 upregulation by most splenic resident leucocytes and peripheral LN cDCs [23, 24] .
MLN but not splenic CD11b high cDCs acquire CLEC-2 following LPS stimulation
In agreement with the results detailed above, CLEC-2 expression was not detected on splenic CD11b high cDCs. However, a modest but significant increase in staining of MLN-derived Clec1b +/+ CD11b high cDCs compared to Clec1b −/− controls was observed after LPS injection (Fig. 2D) , indicating that LPS-stimulated MLN CD11b high cDCs have the capacity to upregulate CLEC-2 (Fig. 2D ).
However, we could not correlate the appearance of CLEC-2 on the membrane with a higher relative amount of Clec1b transcripts in the stimulated CD11b high cDCs (Fig. 2E) , suggesting that LPS stimulation regulates CLEC-2 expression in MLN CD11b high cDCs via posttranscriptional mechanisms. Taken together, our results confirmed high levels of CLEC-2 expression on splenic platelets (data not shown), while no significant expression of CLEC-2 was observed on most leucocyte populations investigated, both at steady state and after LPS injection. However, we did observe an increase in CLEC-2 expression on activated CD11b high cDCs isolated from the MLN. This increase was absent on splenic-activated cDCs. The existence of cell-specific and tissue-specific regulation of CLEC-2 expression has previously been observed in the context of human rheumatoid arthritis, a chronic inflammatory disease where CLEC-2 expression was found to be restricted to tissue infiltrating platelets, while absent from activated DCs [22] . In contrast, FITC skin painting, FITC footpad immunization, or OVA/CFA subcutaneous injections in mice were found to contribute to the generation of an immune response that relies on CLEC-2 expression by activated DCs ratio) that we injected into lethally irradiated C57BL/6 recipients (Supporting Information Fig. 7A ) [47] . The absolute numbers of lymphocytes in the blood, spleen, and MLNs were monitored ( Fig.  3B and C, Supporting Information Fig. 7B and C) . Both in the blood and the SLOs, the absolute numbers of B and T lymphocytes were normal. In the spleen, the numbers of follicular, nonfollicular, and marginal zone Clec1b −/− B lymphocytes were comparable to the controls. Contrary to the MLNs, a small increase in CD4 + T lymphocytes was observed in the spleen of Clec1b −/− animals.
However, no-significant increase in naïve (CD62L hi CD44 int ) or activated (CD44 hi CD62L − ) CD4 + T lymphocytes was noted in these animals. Similarly, the CD4 − T lymphocytes showed the same level of activation between Clec1b −/− and control animals.
These results indicate that deletion of the Clec1b gene in the B-cell lineage has no effect on lymphocyte homeostasis. Despite the absence of a functional Clec1b gene, peripheral blood Clec1b −/− B lymphocytes were stained by 17D9 at the same level as Clec1b +/+ B lymphocytes (Fig. 3D) . In B lymphocyte Clec1b-deficient mice, 71% of the platelets were CLEC-2 pos on average (Fig. 3D) , while the level of CLEC-2 expression by CD11b high Gr-1 high cells was comparable to that found in controls (Supporting Information Fig. 7D) . We compared the amount of Clec1b transcripts by quantitative PCR in B lymphocytes isolated from the peripheral blood, MLNs, and spleen. In all three populations, the amount of Clec1b was extremely low and at a comparable level (Fig. 3E ). This last result corroborates a study on rat B lymphocytes showing that Clec1b transcripts are hardly detectable in these cells [48] . From these observations, we conclude that peripheral blood B lymphocytes do not intrinsically express CLEC-2. Instead we propose that the CLEC-2 molecules detected on the surface of circulating B lymphocytes are derived from MHC-II antigen presentation, trogocytosis, or exosomes/microparticles attached to the B-cell membrane [49] .
Concluding remarks
Our study confirms that CLEC-2 is constitutively expressed by mouse platelets and circulating CD11b high Gr-1 high myeloid cells and shows for the first time that CLEC-2 is present on the surface of peripheral blood B lymphocytes. These B cells do not produce CLEC-2 but likely acquire CLEC-2 molecules from other yet uncharacterized cell types. Our data suggest that both circulating B lymphocytes and CD11b high Gr-1 high myeloid cells lose CLEC-2 when entering SLOs. This loss of CLEC-2 might depend on the same mechanisms that are selectively shedding CD23 and CD62L from leucocytes during transendothelial migration [43, 45, 46] . As CLEC-2 stimulates PDPN pos FRCs in SLOs in order to mount a proper immune response [14, 15, 24] , we propose that the loss of CLEC-2 by naïve B lymphocytes and CD11b high Gr1 high myeloid cells entering in the SLOs might be a prerequisite to prevent untimely FRCs activation in absence of antigenic challenge. The use of animals reconstituted with Clec1b −/− FL and the measurements of Clec1b transcripts allowed us to rule out any constitutive CLEC-2 expression by most of the leucocyte subpopulations isolated from SLOs. We also demonstrated that isotype controls are not adequate when working with the 17D9 antibody clone. Finally, we showed that LPS peritoneal injection induces CLEC-2 acquisition to the unique MLN-activated DCs leucocyte population. Taken together with other studies, our findings emphasize the notion that the expression of CLEC-2 is not only restricted to specific subsets of resting leucocytes and platelets but is determined both by the activation state and anatomical site where immune responses take place. [25] , Rosa26 +/ERT2cre (Jackson Laboratory, ME) [50] , Clec1b
Materials and methods

Mice and diets
and BoyJ mice were maintained in the Biomedical Services Unit, University of Birmingham. C57BL/6 mice were purchased from Harlan, UK. Animals were fed with FormulaLab Diet 5008 (LabDiet, St-Louis, MO). When required, 6-to 8-week-old Clec1b After mRNA isolation and cDNA synthesis, the relative expression of Clec1b transcripts was analyzed by quantitative PCR. The signals for Clec1b was normalized against the house-keeping gene Actnb (β-actin). Total BM was used as positive control and reference to set the arbitrary unit. Each population was isolated from three independent cell sorting experiments, including one to two mice for each cell sorting, and one quantitative PCR was ran from each cell sorting. The graphs summarize these three independent quantitative PCRs pooled together and data are shown as mean + SEM. Statistical significance was measured by a Mann-Whitney test with a 95% confidence interval where: *p < 0.05; **p < 0.005; ***p < 0.0005; N.S, not significant. Whole blood from FL reconstituted animals was drawn into acid citrate dextrose solution (9:1 v/v) from the inferior vena cava under isofluorane anesthesia and mixed to 20 mM EDTA/PBS 1× solution. An aliquot of blood was centrifuged and processed as described above.
The spleen and the MLN were harvested into cold 2% FCS RPMI solution (Sigma-Aldrich). For cell sorting of T cells, B cells, and NK cells, part of the spleen was mechanically dissociated on a 100 mm mesh (Greiner Bio-one). In all the other cases, spleen or MLN were teased apart with dissection forceps in a 2% FCS RPMI solution containing 2.5 mg/mL of Collagenase D (Roche) and 2 mg/mL of DnaseI (Sigma-Aldrich). Cell suspensions were kept under magnetic stirring at 37°C for 45 min before centrifugation. Pellets were resuspended in a 2% FCS RPMI solution containing 2.5 mg/mL of Collagenase/Dispase (Roche) and 2 mg/mL of DnaseI (Sigma-Aldrich) and kept under magnetic stirring at 37°C for 30 min. Cell suspensions were adjusted to a final EDTA concentration of 5 mM by the addition of a 0.5 M EDTA solution and kept under magnetic stirring at 37°C for 5 min. Cell suspensions were centrifuged and the pellets resuspended in red blood cell lysis buffer (Sigma-Aldrich) as described above before processing for FACS staining.
Antibodies, FACS analysis, and cell sorting
The full list of antibodies used is provided in Supporting Information Table 1 . Anti-mouse CLEC-2-FITC 17D9 clone was mainly obtained from a commercial provider (AbD Serotec, 17D9) and compared to rat IgG2b-FITC (AbD Serotec, MCA1125FT). For some experiments, purified 17D9 (a kind gift from Caetano Reis e Sousa, Cancer Research UK, London) and purified rat IgG2b (R&D Systems) were used. Purified anti-mouse CLEC-2 INU1 clone (a kind gift from Bernhard Nieswandt, University of Würzburg, Germany) was used in conjunction with purified rat IgG1k (Biolegend, 400402). All purified antibodies were conjugated to AlexaFluor R 488 using a monoclonal antibody labeling kit (Invitrogen).
Cells were stained with antibodies at 4°C in the dark in PBS 1×, 2% FCS, 2 mM EDTA solution. Cells were washed and centrifuged twice before being resuspended in a cold a PBS 1×, 2% FCS, 2 mM EDTA, 1 mg/mL DAPI solution. Flow cytometry acquisitions were performed on a three laser (405, 488, 633 nm) Cyan (Beckman Coulter) using Summit v4.3 software (Beckman Coulter). Flow cytometry cell sorting was performed on a MoFlo highspeed cell sorter and Astrios cell sorter (Beckman Coulter) using Summit software (Beckman Coulter). FACS data were analyzed with FlowJo software 8.7 (Tristar).
Quantitative PCR
Total BM was flushed with 2% FCS RPMI from the tibia and femur of both hind legs. A tenth of the cell suspension was centrifuged, the supernatant was removed and pellets were snap frozen on dry ice. Flow cytometry cell sorted cells were collected in PBS 1×, 2% FCS, 2 mM EDTA solution, centrifuged, pelleted, snap frozen on dry ice and stored at −80°C. mRNA was extracted using a "RNeasy Microkit" (Qiagen) following the manufacturer's instructions. cDNA was generated using the "High Capacity Reverse Transcription" kit and random primers mix (Applied Biosystems). RT-PCR reaction settings were: 25°C, 10 min; 37°C, 120 min; 85°C, 10 min. The cDNA obtained was diluted 1:2 with RNasefree/DNase-free water (Qiagen), preamplified using the "TaqMan Pre-Amp Master Mix" kit (Applied Biosystems) and the TaqMan probes (Applied Biosystems) specific for murine β-actin (Actnb, probe number: Mm 01205647-g1), β-2microglobulin (B2m, probe number: Mm 00437762-m1) and CLEC-2 (Clec1b, probe number: Mm 0183353-m1). The preamplification PCR reaction settings were 95°C, 10 min followed by ten cycles: (95°C, 15 s; 65°C, 4 min). These preamplified cDNA were diluted 1:5 with RNase-free/DNase-free water (Qiagen). The TaqMan probe-based quantitative PCR was set up on a 384 well/plate using "TaqMan Gene Expression Master Mix"(Applied Biosystems) and the TaqMan probes for the murin Actnb, B2m, and Clec1b mentioned above. The quantitative PCR reactions were run on a 7900HT quantitative PCR machine (Applied Biosystems) at 50°C, 2 min; 95°C, 10 min; 40 cycles: (95°C, 15 s; 60°C, 1 min).
Statistical analysis
All statistical analyses were performed on Prism v4.0 (GraphPad Software, CA) using two-tailed Mann-Whitney tests with 95% confidence interval. 
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